Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Work In Process (2022 - 2024)

Historic Work In Process for Atara Biotherapeutics (ATRA) over the last 3 years, with Q4 2024 value amounting to $9.7 million.

  • Atara Biotherapeutics' Work In Process rose 3147.47% to $9.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $9.7 million, marking a year-over-year increase of 3147.47%. This contributed to the annual value of $9.7 million for FY2024, which is 3147.47% up from last year.
  • According to the latest figures from Q4 2024, Atara Biotherapeutics' Work In Process is $9.7 million, which was up 3147.47% from $12.3 million recorded in Q3 2024.
  • Over the past 5 years, Atara Biotherapeutics' Work In Process peaked at $15.1 million during Q2 2024, and registered a low of $372000.0 during Q4 2022.
  • Moreover, its 3-year median value for Work In Process was $7.4 million (2023), whereas its average is $7.8 million.
  • Per our database at Business Quant, Atara Biotherapeutics' Work In Process soared by 188145.16% in 2023 and then skyrocketed by 3147.47% in 2024.
  • Quarter analysis of 3 years shows Atara Biotherapeutics' Work In Process stood at $372000.0 in 2022, then skyrocketed by 1881.45% to $7.4 million in 2023, then soared by 31.47% to $9.7 million in 2024.
  • Its last three reported values are $9.7 million in Q4 2024, $12.3 million for Q3 2024, and $15.1 million during Q2 2024.